Join the waitlistMeet us
UBi represents a new layer of actively managed care, helping doctors adjust treatment earlier to improve clinical outcomes at scale.
Massachusetts
UBi is getting ready.
Through our conversations, I connect the changes you’re feeling with objective changes in your gut’s biology, so you and your GI can understand how your treatment is working.
That's the approach the AGA, the leading gut experts, recommend, because it's been shown to help more people reach remission.
UBi provides daily conversations, nutrition guidance and practical support.
Our nurses review each patient’s results and care history to help their GI decide whether treatment needs to change.
UBi’s pre-emptive, biomarker-driven care proves treatments are actually working and escalates failing ones months before the standard of care would notice.
This is how programs designed like UBi’s drive:
Higher mucosal healingCALM trial, Lancet 2017
Lower risk of disease progressionCALM follow-up, 2020
Lower cost of care per patient each year on advanced therapiesSonarMD · UPMC, 2018 · TAXIT, 2015
Through daily conversations, nutrition guidance and support through the hard days, UBi learns how each patient lives and feels.
Patients talk with UBi about food, meds, questions and the bad days, by voice or text at any hour, and she turns what they share into structured clinical information for their doctor.
UBi connects biomarker testing with symptoms, treatment, nutrition and wearable trends to understand how each patient’s individual biology responds to care.
The practice refers patients, and UBi takes care of their enrollment and first conversation.
Patients get answers from UBi and the UBiosis team instead of calling the front desk. She flags the patients whose treatment has quietly stopped working before they end up in the ER.
Conversations, symptoms and test results arrive in the chart where the care team already works.
She gathers the biomarker history and records an insurer asks for, and the office submits the request with that support already in hand.
She walks each patient through the prep on the right days and confirms they are ready the morning before the procedure.
An IBD care pathway, with the patient’s own gastroenterologist directing treatment.
Pick a condition to see the trials behind the way UBi works, what they showed, where UBi carries each step between visits, and what that does to the cost of care.
Treat-to-target care, carried all the way to a healed scope, is what makes deep remission real.
Deep remission, meaning symptoms, scope and steroids all clear, is the goal that changes the course of IBD. Care that keeps checking every day gets more people there and keeps them there, at a fraction of what it costs today to get one person well.
Treat-to-target care, carried all the way to a healed scope, is what makes deep remission real.
In CALM, therapy was stepped up when calprotectin reached 250 µg/g, CRP 5 mg/L or symptoms rose, rather than on symptoms alone. Mucosal healing at 48 weeks went from 30% to 46%, a 16-point difference.5
UBiUBi runs the monitoring half of that loop, so the GI’s escalation decisions get made on time.
Across 19 studies calprotectin found active inflammation with 88% sensitivity and 73% specificity against endoscopy. A value at or under 250 µg/g ruled out active ulcers with a 96.6% negative predictive value.6
UBiScheduled calprotectin tells us whom to send for the scope sooner. It never stands in for it.
In a pooled analysis of 19 studies, mucosal healing predicted fewer major surgeries (RR 0.34) and fewer hospitalizations (RR 0.58), with the same pattern in Crohn’s and UC.7
UBiThe scope is where healing gets confirmed. UBi makes sure it happens and that the patient arrives prepared.
Patients in deep remission at the end of CALM (clinical remission, no ulcers on scope, no steroids) had a far lower risk of new strictures, fistulas, hospitalization or surgery over the next three years, whichever arm they had been in.8
UBiThat is why UBi works toward the confirming endoscopy and not just a quiet patient.
Each of these put a nurse or a daily check-in between the patient and the GI. Every one of them cut unplanned care; the savings tracked engagement, and engagement is what UBi is built for.
Net 9.87% savings after the program fee, over $1,000 per patient. Engagement went from 27% to 75–80% once check-ins moved to text, and the savings tracked the engaged patients.12
Disease activity scores and quality of life also improved. Patients on steroids or opioids at enrollment were the ones who kept coming back, which is who a daily check-in is for.9
A telemonitoring app with nurse follow-up cut admissions in half and outpatient visits by a third (1.55 vs 2.34 a year) with the same quality-of-care scores.13
Across every randomized e-health trial in IBD, patients went to the emergency department less and to the office less, with no loss of disease control.14
GI emergency visits 4% vs 10%, imaging 15% vs 44%. Mostly IBS and other gut-brain disorders; the IBD subgroup trended the same way.15
Tight control on its own moves spend from the hospital to the pharmacy: in CALM, Crohn’s hospitalizations fell 58% while adalimumab use rose 26%. The savings arrive when the drug side is managed with the same discipline, and every lever below has been shown in its own study. Values are our model per patient on advanced therapy, a year, central and optimistic.
Anchored to the randomized trials (about 17% of unplanned-care spend), below what SonarMD and UPMC measured.14
$2,700$6,000Checking drug levels at loss of response cut infliximab escalations from 71% to 45% with the same response rate and 15% lower cost; in a randomized trial the level-guided path cost 34% less than dose intensification, again with the same response.16
$1,050$2,250In TAXIT, 93% of patients above the target trough were dose-reduced to range, cutting drug cost 28%, and concentration-based dosing had fewer flares (7% vs 17%).10
$2,160$5,250With a nurse present at the switch, 91.8% of patients accepted an adalimumab biosimilar and 90.4% kept clinical remission at 12 months. The adalimumab gap runs about $19K a year at net prices.17
$1,500$4,000Across 52,760 infusions, hospital outpatient departments cost 41.9% more with no difference in adverse events, admissions or ER visits.18
$2,000$5,000Calprotectin at $30 to $60 a test, and the earlier escalations tight control brings (CALM +26% adalimumab, SonarMD +9% infusibles).19
−$500−$300About $3,350 averaged across a whole IBD panel, where 28% of patients are on advanced therapy.22
$8,900$22,200For patients on conventional therapy the value is biologic starts averted when monitoring proves the current treatment is working, about $5,000 a year for the patient with a flare or steroid course in the past year: 87.5% of patients with a normal calprotectin and no change in therapy stayed in remission over the next three months, steroid courses grow from 34 to 88 days a year across the five years before a biologic start, and non-adherent patients in remission relapse 5.5 times as often.21
A simulated panel of 1,000 IBD patients, usual care against UBi, month by month for 36 months, built by chaining the studies above: CALM sets the deep remission reached in year one, TAXIT sets how many remitters relapse each year on symptom-led versus level-guided dosing, the CALM follow-up sets how much less often patients in deep remission progress, and the lever model sets the cost. The line is the central case; where there is a band it reaches the optimistic case.
Year one is CALM: 36.9% against 23.0%. After that UBi keeps the loop running: patients not yet in deep remission keep converting at the same rate while remitters relapse at 7% a year on level-guided dosing. Usual care holds where it is, which is what IBD Qorus measured across 41 practices. At two years 58% against 23%; at three 69%.23
Each month’s risk follows the mix: patients in deep remission progress at HR 0.19 (Ungaro), and usual care is pinned to what REACT measured in 39 community practices, 35.1% by two years. The gap compounds as the deep-remission share widens: 35% against 30% at two years, 47% against 38% at three. REACT’s early-combined arm, the lower dot, measured 27.7%.24
$33,000 a year falls to $29,649 (central) and $25,151 (optimistic) once every lever is running. Over three years that is $8,831 to $20,685 saved per patient across the panel, and $23,550 to $58,506 per patient on advanced therapy.22
Today’s biologics run about $700K per remission at list price (adalimumab $750K, ustekinumab $788K). It compounds: the same drug dollars buy 2.5 times the deep remissions at two years and 3.0 at three, and the de-escalation and switch levers grow with the remission pool, taking 13% then 15% off spend. Cost per remission falls to about $243K at two years (−65%) and $197K at three (−72%); $133K in the optimistic case.4
Simulation inputs: deep remission at 48 weeks 23.0% vs 36.9% (CALM, posted trial results); relapse out of remission 17% vs 7% a year (TAXIT, clinical vs concentration-based dosing); HR 0.19 for major adverse outcomes in deep remission (Ungaro) with the real-world level set by REACT’s conventional arm, 35.1% at 24 months, giving an annual hazard of 26% outside deep remission and 4.9% inside it; $33,000 a year per patient (Park, 2026 dollars); whole-panel savings $3,351 central and $7,849 optimistic per patient-year from the lever model, realized 25% by month 3, 75% by month 6 and fully from month 12; cost per remission from $700K on today’s biologics (Jairath), divided by the deep-remission ratio, with the drug levers growing with the remission pool (15% to 43% of drug spend by year three). Usual care reaches CALM’s conventional-arm deep remission in year one and holds there (IBD Qorus: site-level remission unchanged across 41 practices); if it instead kept converting at the trial rate, cost per remission would still be 45% lower at three years. UBi has no outcomes data of its own yet; this is the projection the studies support, and the one our first-practice data will be measured against.
The IBS care the guidelines call for, delivered every day: the right diagnosis, the diet done properly, and a next step when symptoms don’t settle.
IBS costs twice what a matched patient costs, and almost all of it is scans, scopes and emergency visits rather than the IBS itself. The care that works is a diet done with a dietitian, the right first medicines and gut-directed therapy, and it works when someone is there every day.
The IBS care the guidelines call for, delivered every day: the right diagnosis, the diet done properly, and a next step when symptoms don’t settle.
In a randomized trial of integrated care (gastroenterologist, dietitians, gut-focused psychology) against GI-only care, global improvement was 84% versus 57% and the IBS subgroup’s severity response 66% versus 38%. Single centre, in person, open-label.5
UBiThis is the care model UBi delivers between visits, with the practice’s GI directing it.
IBS severity fell from 227 to 146 among engaged patients, and GI-related cost was $5,316 a year lower than matched controls. Observational, from a comparable program rather than UBi.4
UBiDaily contact is what catches the bad week before it becomes a scan or an ER visit.
Low-FODMAP ranked first among diets in a network meta-analysis of 13 trials (RR 0.67 for symptoms not improving), and ACG says all three phases must be taught. Most trials never studied reintroduction, which is where patients get stuck on their own.6
UBiUBi runs the restriction, reintroduction and personalization phases meal by meal, and knows which foods came back.
Soluble fiber carries a strong ACG recommendation (NNT 7, moderate quality); peppermint oil and gut-directed psychotherapy are conditional with low-quality evidence (NNT 4). For IBS-D, rifaximin gave adequate relief in 41% versus 32%; for IBS-C, linaclotide met the FDA endpoint in 34% versus 14%.7
UBiUBi delivers the first-line steps every day and tracks the response, so the GI escalates to a drug on data.
Reflux care the way the guidelines say: a proper trial of the acid blocker, a step down when it works, and a test before any escalation when it doesn’t.
Half the people on a daily PPI, the standard acid blocker, still get reflux twice a week, and when they are referred as refractory, meaning the drug isn’t working, four in five turn out to have a dose, timing or diagnosis problem instead.
Reflux care the way the guidelines say: a proper trial of the acid blocker, a step down when it works, and a test before any escalation when it doesn’t.
Of 366 patients, 42 were relieved by two weeks of twice-daily omeprazole, 99 had functional heartburn and 23 had another esophageal disorder. Only 78 had reflux disease that was truly refractory.5
UBiThe guideline says test first and stop the PPI if testing is negative. UBi gets non-responders to that workup.
A mailed brochure and a letter to the GP doubled the share of long-term users who cut their dose in half, with no difference in reflux-impact scores.6
UBiThat was a one-letter intervention. UBi stays with the patient through every step down and catches the ones who relapse.
One 20-minute visit with a trained nurse, an action plan and rescue therapy. 8.7% went back to their original dose. The study had no control group and the authors were affiliated with the rescue-therapy maker.7
UBiThe closest published analog to UBi’s step-down coaching, with its caveats shown.
On-demand use takes 3.8 fewer pills a week; it also leaves more breakthrough symptoms, so it suits non-erosive disease, which is where the guideline suggests it.8
UBiUBi knows which patients have erosive disease on file and keeps them on maintenance, and moves the rest to on-demand.
GLP-1 stewardship: get people through the dose ramp, measure the response, and stop the drug when it isn’t working.
Two in three people quit a GLP-1 in the first year, most of them during titration, the dose ramp where the nausea peaks. Daily support gets them through it, and a measured weight tells the prescriber whether to continue or stop.
GLP-1 stewardship: get people through the dose ramp, measure the response, and stop the drug when it isn’t working.
Starting lower and stepping up weekly, with a pause whenever GI symptoms flared, cut withdrawals for side effects from 19% to 2% with the same glucose and BMI results. A small open-label trial in type 2 diabetes.5
UBiUBi hears about the nausea the day it starts and adjusts the pace with the prescriber, before the patient quits.
Stopping within three months bought almost nothing. Each 1% of weight lost was itself associated with a 3.3% lower hazard of stopping, so showing patients their measured progress helps them stay.6
UBiUBi’s daily contact and the scale on the floor are what carry a patient from month two to month twelve.
Weight loss was the same whether or not patients had nausea or vomiting, and 98% of GI events were mild to moderate. Treating the symptoms is free of cost to the result.7
UBiSo UBi treats them: hydration, meal timing, antiemetics by the prescriber’s protocol, and a slower step when needed.
The Endocrine Society, AACE, the ADA and payer renewal policies all set the bar at 5% after about three months on the maintenance dose, documented. Only 1.7% of real-world stops are for poor weight loss, which suggests the rule rarely gets applied.8
UBiUBi’s measured weights make the rule enforceable, in both directions.
In EoE symptoms don’t track the biology, so UBi keeps people on treatment and gets them to the scope that confirms healing.
By the time swallowing gets hard again, four in five people have already relapsed on biopsy, the tissue sample that shows whether the esophagus has healed, and each gap in care adds scarring a scope can’t undo.
In EoE symptoms don’t track the biology, so UBi keeps people on treatment and gets them to the scope that confirms healing.
In 269 adults, symptom scores detected histologic remission with an area under the curve of 0.60. After stopping topical steroids, 78% of patients had relapsed on biopsy by the time symptoms recurred. ACG 2025 advises against monitoring symptoms alone.3
UBiSo UBi treats the confirming scope as the endpoint, not the quiet patient.
In a randomized withdrawal trial, 73.5% to 75% of patients kept on maintenance budesonide stayed in remission at 48 weeks against 4.4% on placebo. In a Swiss cohort, swallowed topical steroids cut the odds of a food impaction needing endoscopy by about 60% (OR 0.41).5
UBiPatients stop steroids when they feel fine. UBi is the daily reason they don’t.
After a gap in care of two years or more, 37% of patients developed new fibrotic features, 12% presented with a food impaction, and the odds of a stricture rose 26% for each year of the gap. Structured annual follow-up was associated with fewer strictures.6
UBiUBi notices the patient who has gone quiet, and brings them back before the gap costs them.
Experts check adherence (98%), dosing (92%) and technique (90%) before calling a patient refractory. Patients with excellent adherence to topical steroids had a 64% histologic response against 54% overall. ACG 2025 says to confirm response by biopsy 8 to 12 weeks after a new therapy, or 12 to 24 for dupilumab.7
UBiUBi coaches the dose and the technique every week, so the first-line drug gets a fair trial before anyone escalates.
The trial results describe the clinical approach UBi runs under the patient’s own GI, not a UBi trial; the treatment decisions in every study were the physician’s. Economics are modeled from published trials, claims studies and national rates, shown as the central case with the range in the sources.
UBi and our clinical team handle daily support, monitoring and documentation, giving your staff time back and your practice a new line of reimbursable care.
of staff work handled each year, per 1,000 IBD patients
Estimated from published IBD call, portal-message and care-management volumes.“UBi guided me through specific questions I didn’t even know to ask: How many times am I eating? What did I eat today?”
New IBD patient, describing their experience with UBi
“It’s like having a dedicated nurse available 24/7 for each patient.”
Dr. Allan Weston, Past ACG Governor for Missouri and Kansas
“UBiosis’s commitment to evidence-based patient monitoring and updates delivered to the clinic promises to transform our patient care by enabling proactive, personalized interventions tailored to each individual.”
Dr. Richard Manfready, Gastroenterologist
Care pathways shaped around the condition and the individual.
Pre-emptive care uses biological changes to help investigate a problem before symptoms alone would bring it to attention. UBi connects those changes with the patient's daily experience, while the nursing team reviews proposed escalations and their doctor decides whether to investigate or adjust treatment.
UBi is live for IBD today and is being built for broader GI care. The practice confirms which pathways are available and appropriate for each patient.
The patient's own gastroenterologist directs treatment. UBi supports the patient day to day and helps carry out the doctor's plan, while the nursing team reviews findings and proposed escalations before they reach the GI.
Patients can use voice conversations and the app to discuss questions, describe their experience and receive support within their care plan.
Tests and measurements are selected for the patient's condition and care plan under their doctor's direction. The information gathered depends on what is clinically useful for that individual.
Coverage depends on the patient’s plan, eligibility and the services provided. The practice confirms the applicable arrangements before enrollment.
UBi uses conversations, check-ins and biomarker results to personalize support and help the care team review treatment response. Patients receive the program's privacy information and consent details before enrollment.
Patients should follow their practice’s instructions for urgent symptoms and contact the practice when prompt clinical attention is needed. For an emergency, call 911.
Patients can ask their gastroenterologist about participating or contact our team to learn more about the service.
Start with an intro call, agree standing orders and enroll your first patients. The demonstration covers the clinical pathway, the GI's role and how our team handles enrollment, monitoring and documentation.
Patients can ask about care with UBi alongside their GI, while practices can book an introduction to get their first patients started.
